2nd IBERO-AMERICAN MEETING ON TOXICOLOGY AND ENVIRONMENTAL HEALTH

2^nd IBERO-AMERICAN MEETING ON TOXICOLOGY AND ENVIRONMENTAL HEALTH

June 17^th – 19^th, 2013 (Ribeirão Preto, Brazil)

Dear colleagues,

We are pleased to announce the “2^nd IBERO-AMERICAN MEETING ON TOXICOLOGY AND ENVIRONMENTAL HEALTH” (IBAMTOX 2013), which will take place in Ribeirão Preto (SP, Brazil), from the 17^th to the 19^th of June 2013. IBAMTOX 2013 offers a unique forum focusing on basic and applied aspects of toxicology and environment. It will provide an opportunity for toxicologists, chemists, scientists, clinicians and academics to network and present their research data, as well as to discuss current themes such as risk assessment, air pollution, biomonitoring, emerging contaminants, nanotoxicology, gene-environment interactions, legislation and many more.

Papers originated from IBAMTOX 2013 will be published in a special issue of the Journal of Toxicology and Environmental Health (JTEH) by Taylor & Francis. Moreover, JTEH, represented by its Editor, Dr. Sam Kacew, will provide a Taylor & Francis Book Awards for the three best student presentations in the amount of $ 200 each.

The deadline for abstract submission is April 12^nd, 2013.

Several recognized scientists have confirmed their presences as speakers during IBAMTOX 2013:

· Andres Campíglia - University of Central Florida, Orlando, USA

· Cristina Carvalho - University of Lisbon, Portugal

· Daniel Cyr - Université du Québec, Canada

· Ellen Silbergeld - Johns Hopkins University, USA

§ Editor-in Chief - Environmental Research

· Francisco J. R. Paumgartten - Fundação Osvaldo Cruz, Brazil

· Jean-Philippe Chippaux - University Paris Descartes, France

· João Batista Teixeira da Rocha - Universidade Federal de Santa Maria, Brazil

· João Paulo Teixeira - INSA, Portugal

· Kurunthachalam Kannan - State University of New York, USA

§ Editor-in Chief - Ecotoxicology and Environmental Safety

· Leslie V. Boyer-Hassen - University of Nebraska Medical Center, USA

· Michael Aschner - Vanderbilt University Medical Center, USA

§ Associated Editor - Toxicological Sciences; Neurotoxicology

· Patrick Jeremy Parsons - State University of New York, USA

· Paul Tchounwou - Jackson State University, USA

 

§ Editor-in-Chief - Environmental Toxicology

· Paulo Saldiva - Universidade De São Paulo, Brazil

· Sally Perreault Darney - Environmental Protection Agency, USA

§  Associate Editor - Molecular Reproduction and Development

· Sam Kacew - University of Ottawa, Canada

§ Editor-in-Chief – Journal of Toxicology and Environmental Health (JTEH) Parts A and B

· Sergio Koifman - Fundação Osvaldo Cruz, Brasil

· Susana Viegas - Higher School of Health Technology of  Lisbon, Portugal

· Thomas Knudsen - U.S. Environmental Protection Agency, USA

§ Editor-in-Chief - Reproductive Toxicology (RTX)

· Wilma de Grava Kempinas - UNESP Botucatu, Brazil

 

Additional information can be seen at http://www.ibamtox.com.br/2013/

If you are a professional or academic with interest in Toxicology and Environmental Health, we will be happy and honored to welcome you to IBAMTOX 2013!

PLEASE DIVULGE OUR MEETING AMONG YOUR PEERS.

Sincerely yours,

 

Organizing Committee

IBAMTOX 2013

Planta Medica

Dear Colleague, Planta Medica issue 5 contains the abstracts of the 12th Annual Oxford International Conference on the Science of Botanicals (ICSB, April 15Gingerol: A Novel AT1 Antagonist for the Treatment of Cardiovascular Disease Qing Liu, Jinjin Liu, Haili Guo, Shengnan Sun, Shifeng Wang, Yanling Zhang, Shiyou Li, Yanjiang Qiao Abstract | HTML | PDF Letters FREE ARTICLE: Sarothrin from Alkanna orientalis Is an Antimicrobial Agent and Efflux Pump Inhibitor Jessica R. Bame, Tyler N. Graf, Hiyas A. Junio, R. Owen Bussey III, Scott A. Jarmusch, Tamam El-Elimat, Joseph O. Falkinham III, Nicholas H. Oberlies, Richard A. Cech, Nadja B. Cech Abstract | HTML | PDF FREE ARTICLE: Antileishmanial Activity of 5-Methyl-2,2' : 5',2"-terthiophene Isolated from Porophyllum ruderale is Related to Mitochondrial Dysfunction in Leishmania amazonensis Helena Teru Takahashi, Elizandra Aparecida Britta, Renata Longhini, Tânia Ueda-Nakamura, João Carlos Palazzo de Mello, Celso Vataru Nakamura Abstract | HTML | PDF Unusual Amino Acids and Monofluoroacetate from Dichapetalum michelsonii (Umutambasha), a Toxic Plant from Rwanda Virginie Esters, Charles Karangwa, Monique Tits, Pierre Francotte, Bernard Pirotte, Anne-Catherine Servais, Marianne Fillet, Jacques Crommen, Elmar Robbrecht, Arlette Minet, Thierry Grisar, Luc Angenot, Michel Frederich Abstract | HTML | PDF Natural Product Chemistry Original Papers Sesquineolignans and Terpene-Sesquineolignans: Anti-Acetylcholinesterase Constituents from Illicium simonsiith–18th, 2013, University of Mississippi, University, MS, USA). Nevertheless a reduced number of regular contributions are included as well. Cardiovascular diseases are associated with high morbidity, mortality, and financial burden to health care services. In their search for novel compounds targeting the angiotensin II type 1 receptor, accepted as a therapeutic target in cardiovascular disease, Liu et al. have characterised [6]-gingerol from Zingiber officinale (ginger) as a novel antagonist of this receptor.         Botanicals have been suggested as an under-utilized source of antimicrobial agents. Bame et al. have identified the flavonoid sarothrin from Alkanna orientalis as an antimicrobial agent and efflux pump inhibitor. Leishmaniasis is a group of diseases caused by protozoa parasites of the genus Leishmania. The drugs used in leishmaniasis treatment present several problems, including high toxicity and many adverse effects, and there is a high need for new and better therapeutic agents. Takahashi et al. have reported that the antileishmanial activity of 5-methyl-2,2':5',2"-terthiophene isolated from Porophyllum ruderale is related to mitochondrial dysfunction in Leishmania amazonensis. It is my pleasure to offer you free access to these publications.       Sincerely, Luc Pieters Planta Medica, Editor-in-Chief         CONTENTS ·         [6]-Gingerol: A Novel AT1 Antagonist for the Treatment of Cardiovascular Disease ·         Sarothrin from Alkanna orientalis Is an Antimicrobial Agent and Efflux Pump Inhibitor ·         Antileishmanial Activity of 5-Methyl-2,2':5',2"-terthiophene Isolated from Porophyllum ruderale is Related to Mitochondrial Dysfunction in Leishmania amazonensis ·         Table of Contents: Issue Issue 5, March 2013             [6]-Gingerol: A Novel AT1 Antagonist for the Treatment of Cardiovascular Disease (FREE ACCESS) Qing Liu, Jinjin Liu, Haili Guo, Shengnan Sun, Shifeng Wang, Yanling Zhang, Shiyou Li, Yanjiang Qiao         Considering the prevalence of cardiovascular disease in public health and the limited validated therapeutic options, this study aimed to find novel compounds targeting the angiotensin II type 1 receptor, accepted as a therapeutic target in cardiovascular disease.       A small library consisting of 89 compounds from 39 Chinese herbs was profiled using a cell-based calcium mobilization assay which was developed and characterized for high-throughput screening. [6]-Gingerol from Zingiber officinale Roscoe (ginger) was identified as a novel angiotensin II type 1 receptor antagonist, with an IC50 value of 8.173 μM. The hit was further tested by a specificity assay indicating that it had no antagonistic effects on other evaluated GPCRs, such as endothelin receptors. The major ingredient of ginger, [6]-gingerol, could inhibit angiotensin II type 1 receptor activation, which partially clarified the mechanism of ginger regulating blood pressure and strengthening heart in the cardiovascular system. Read more         top   Sarothrin from Alkanna orientalis Is an Antimicrobial Agent and Efflux Pump Inhibitor (FREE ACCESS) Jessica R. Bame, Tyler N. Graf, Hiyas A. Junio, R. Owen Bussey III, Scott A. Jarmusch, Tamam El-Elimat, Joseph O. Falkinham III, Nicholas H. Oberlies, Richard A. Cech, Nadja B. Cech         An Alkanna orientalis leaf and flower extract inhibited the growth of Staphylococcus aureus, a pathogen that causes an estimated 478,000 hospitalizations in the US annually. Bioassay-guided fractionation of A. orientalis resulted in isolation of the flavonoid sarothrin (5,7,4'-trihydroxy-3,6,8-trimethoxyflavone), which inhibited the growth of Mycobacterium smegmatis (MIC 75 μM) and S. aureus (MIC > 800 μM), and possessed efflux pump inhibitory activity.         This is the first report of antimicrobial or efflux pump inhibitory activity of sarothrin, and of its presence in A. orientalis. These findings suggest that the effectiveness of A. orientalis extracts is due to a combination of multiple constituents, including sarothrin. Read more         top   Antileishmanial Activity of 5-Methyl-2,2':5',2"-terthiophene Isolated from Porophyllum ruderale is Related to Mitochondrial Dysfunction in Leishmania amazonensis (FREE ACCESS) Helena Teru Takahashi, Elizandra Aparecida Britta, Renata Longhini, Tânia Ueda-Nakamura, João Carlos Palazzo de Mello, Celso Vataru Nakamura         Recently, this research group isolated 5-methyl-2,2':5',2"-terthiophene (compound A) and 5'-methyl–[5–(4–acetoxy-1–butynyl)]–2,2'-bi-thiophene (compound B) from the aerial parts of Porophyllum ruderale, and reported their antiproliferative activity in promastigotes and axenic amastigote forms of Leishmania amazonensis. Here it was demonstrated that both compounds exhibited activity against intracellular amastigotes showing IC50 values of 37 and 51 μg/mL for compounds A and B, respectively.       Both compounds showed low levels of toxicity for human cells, even at the highest concentrations (hemolytic index < 10% at 500 μg/mL). Promastigotes treated with compound A showed an alteration in the mitochondrial membrane when observed by flow cytometry through labeling with rhodamine 123 and this was confirmed by transmission electron microscopy. Alterations on morphology (rounded cells) were observed by scanning electron microscopy in parasites treated with the compounds. Further studies should be performed employing compounds A and B for the development of new drugs for chemotherapy of leishmaniasis. Read more         top   Table of Contents: Issue Issue 5, March 2013 Biological and Pharmacological Activity Original Papers Neuroprotection of a Novel Synthetic Caffeic Acid-Syringic Acid Hybrid Compound against Experimentally Induced Transient Cerebral Ischemic Damage In Hye Kim, Bing Chun Yan, Joon Ha Park, Go Heum Yeun, Yongbae Yim, Ji Hyeon Ahn, Jae-Chul Lee, In Koo Hwang, Jun Hwi Cho, Young-Myeong Kim, Yun Lyul Lee, Jeong Ho Park, Moo-Ho Won Abstract | HTML | PDF FREE ARTICLE: [6]- Chuanfu Dong, Lei Liu, Xiaonian Li, Zhengye Guan, Huairong Luo, Yifen Wang Abstract | HTML | PDF New Flavonol and Diterpenoids from the Endophytic Fungus Aspergillus sp. YXf3 Tong Yan, Zhi Kai Guo, Rong Jiang, Wei Wei, Ting Wang, Ye Guo, Yong Chun Song, Rui Hua Jiao, Ren Xiang Tan, Hui Ming Ge Abstract | HTML | PDF Cytotoxic Triterpenoid Saponins from the Stems of Gordonia longicarpa Jia Tang, Lei Yu, Huizheng Fu, Chuangjun Li, Jingzhi Yang, Wanqi Zhou, Xiaoguang Chen, Dongming Zhang Abstract | HTML | PDF Letters Phenolic Constituents from the Twigs of Euonymus alatus and Their Cytotoxic and Anti-inflammatory Activity Ki Hyun Kim, Sang Keun Ha, Sang Un Choi, Sun Yeou Kim, Kang Ro Lee Abstract | HTML | PDF Cytotoxic Pentacyclic Triterpenoids from Prinsepia utilis Bin Guan, Cheng-Cheng Peng, Qi Zeng, Xiang-Rong Cheng, Shi-Kai Yan, Hui-Zi Jin, Wei-Dong Zhang Abstract | HTML | PDF Click here to see the full table of contents for this issue.   About this Journal Editor in Chief: Luc Pieters, Belgium Planta Medica is one of the leading international journals in the field of medicinal plants and natural products with original research papers, letters, rapid communications, reviews, minireviews and perspectives from researchers worldwide. Authors, please submit your manuscripts electronically to: http://mc.manuscriptcentral.com/plamed. For further information about Planta Medica, please visit www.thieme.de/plantamedica   © Thieme Medical Publishers, Inc. 2008-2013, All Rights Reserved 333 7th Ave., New York, NY Americas customerservice@thieme.com f:1-212-947-1112 p:1-212-760-0888 Europe, Asia, Africa, Australia customerservice@thieme.de f: +49-711-8931-410 Impressum   This email was sent to cechinel@univali.br. If you are no longer interested you can unsubscribe instantly.

DEFESA DE DISSERTAÇÃO

Seminário

Laboratórios ganham conexão on-line com centros de pesquisa

Software permite que companhias farmacêuticas obtenham informações sobre 400 mil centros de pesquisa clínica no mundo. No vasto universo da internet - que até fevereiro contava com 631,5 milhões de sites ativos, de acordo com a consultoria Netcraft - é cada vez mais difícil encontrar um segmento não explorado para desenvolver um projeto inovador. Mas um grupo de brasileiros encontrou uma área ainda sem um grande concorrente internacional: o relacionamento entre a indústria farmacêutica e centros de pesquisa que testam medicamentos em fase de estudo.   De acordo com dados da Federação Internacional de Associações de Indústrias Farmacêuticas (IFPMA, na sigla em inglês), as pesquisas clínicas movimentam no mundo em torno de US$ 50 bilhões por ano. O custo médio para se testar um medicamento em pessoas é de US$ 150 mil por centro de pesquisa. No mundo, existem em torno de 400 mil centros de pesquisas clínicas, mas encontrar a unidade mais adequada para testar determinado medicamento não é uma tarefa simples. "É muito comum uma indústria contratar um centro e descobrir, no meio do processo, que ele não possui o número desejado de pessoas para realizar os testes, ou não conseguirá testar o medicamento no prazo adequado", afirmou Fábio Thiers, presidente da ViS Research.   Thiers desenvolveu o projeto da companhia novata enquanto cursava pós-doutorado em ciências da saúde e tecnologia na Universidade de Harvard, nos Estados Unidos. Em parceria com Dan Martines, especialista em tecnologia da informação (TI), e com o médico Gustavo Kesselring, Thiers desenvolveu um software, acessado pela internet, que permite às companhias farmacêuticas obterem informações sobre 400 mil centros de pesquisa clínica no mundo. A ferramenta oferece informações como localização do centro, número de pesquisadores, áreas de estudos, número de pacientes disponíveis para testes e equipamentos disponíveis. O serviço também compara o desempenho dos centros por área de pesquisa. A busca é similar à realizada pelo serviço de mapas do Google. Basta selecionar o tipo de pesquisa e os países onde a empresa pretende realizar os estudos e o software apresenta, de forma quase imediata, um mapa dos centros disponíveis.   O cadastro dos centros de pesquisa é gratuito. As companhias farmacêuticas pagam por pacotes de dados, que variam de US$ 500 mil a US$ 2 milhões. O valor parece alto, mas não se compara à economia que as empresas podem ter com o serviço, disse Thiers. "O custo das pesquisas clínicas varia de US$ 1 bilhão e US$ 5 bilhões e a escolha do centro de pesquisas certo pode trazer uma economia de 10% a 20%."   A ferramenta da ViS Research foi desenvolvida com um investimento de US$ 5 milhões, feito pelos sócios. A empresa tem sete patentes registradas e conta com escritórios no Brasil, nos Estados Unidos e na Índia. A proposta é ter uma atuação global. Gustavo Kesselring, diretor de engajamento de centros de pesquisa da ViS Research, disse que, atualmente, dez das maiores empresas farmacêuticas do mundo já testaram a ferramenta, que começa a ser vendida neste mês. "A expectativa é que sejam realizadas 300 pesquisas com a ferramenta já neste semestre, com a produção de 2 mil medicamentos", afirmou.   Os sócios da ViS Research planejam fazer neste semestre uma nova rodada de investimentos. A meta é atrair entre US$ 5 milhões e US$ 10 milhões de fundos de investimentos. (Valor)

 

Reunião Grupo de Pesquisa